Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Pharmacology 080912
| Question | Answer |
|---|---|
| What phase is in the clinical trial where the study design is double-blind/cross-over? | Phase 3 |
| Not a non-receptor mediated interaction | Ligand-gated channels |
| Type of test done to determine gross and histologic pathology | Carcinogenic potential testing |
| Not extracted from quantal-dose response curve | Potency (EC50) |
| Drug that's located within the cell nucleus | Steroid receptors |
| Drug whose N-terminal is extracellular and C-terminal is intracellular | Metabotropic receptor |
| Drug that prevents storage of acetylcholine | Vesamicol |
| Enzyme that catalyzes transfer of an acetyl group from acetylcoenzymeA to Choline is | Choline acetyltransferase |
| Adverse drug reaction that has physical and emotional dependence on drug | Addiction |
| Primary neurochemical mediator of sympathetic and parasympathetic preganglionic neurons | Acetylcholine |
| Non-classical neurotransmitter | Adenosine triphosphate |
| Inhibitor of catechol-o-methyltransferase | Entacapone |
| Not an attribute of the sympathetic division of ANS | short, unmyelinated postganglionic fibers |
| Conversion of norepinephrine to epinephrine is mediated by the enzyme | Phenylethanolamine-N-methyltransferase |
| Rate limiting step in NE synthesis is mediated by enzyme | Tyrosine hydroxylase |
| Not a monoamine oxidase inhibitor | Metyrosine |
| Organ that doesn't have alpha1 adrenergic receptors | Medulla oblongata |
| Organ that doesn't have multiple adrenergic receptors with opposing response | Gastrointestinal muscle |
| Alpha1 agonist drug that's not clinically used to treat shock | Phenylephrine |
| Alpha1-antagonist drug helpful in diagnosing pheochromocytoma at bedside | Phentolamine |
| Alpha2-agonist drug whose effect results to hypotension and bradycardia | Clonidine |
| Not a clinical manifestation of cholinesterase inhibitor intoxication attributable to muscarinic receptors | Weakness |
| Not a beta antagonist | Isoproterenol |
| Not an indirectly acting cholinergic agent | Choline esters |
| Nicotinic receptors are located in | Central Nervous system |
| Muscarinic agonist clinically used to treat open-angle glaucoma | Pilocarpine |
| Clinical manifestation of cholinesterase inhibitor intoxication attributable to nicotinic receptors | Fasciculations |
| Not a bezold-jarisch reflex | Sweating |
| Uptake 1 Blocker | Tri-cyclic anti depressant |
| Catecholamine release inhibitor | Guanithidine |
| Dopa decarboxylase blocker | Carbidopa |
| NE storage blocker | Reserpine |
| Ach storage blocker | Vesamicol |
| Promotes Ach release | Latrotoxin |
| Precursor transport blocker | Disulfiram |
| Baclofen | Partial GABA agonist |
| Dantrolene | Malignant hyperthermia |
| Tubucurarine | Non-depolarizing NM blocker |
| Succinylcholine | Depolarizing NM blocker |
| Sarin | War nerve gas |
| Neostigmine | Quarternary amine |
| Nicotine | Bezold-jarisch reflex |
| Yohimbine | Aphrodisiac |
| Propanolol | Thyrotoxicosis |
| Tyramine | Cheddar cheese |
| Therapy of Cholinesterase Inhibitor Intoxication for Severe Poisoning | 1. Artificial Respiration 2. Atropine sulfate (2-4g intravenous at a 5 minute interval) 3. Pralidoxine (1g infused slowly) 4. Termination of exposure 5. Diazepam for if there's convulsion 6. Supportive Care 7. Hospitalization for 2-3 days |
| Phase II metabolism of the drug that involves all of the following reaction types but not | Deduction |
| Not a type of major bonding | Atomic |
| Not a major plasma protein important for drug binding | Flavoprotein |
| Not a parenteral route of drug administration | Transdermal |
| Drug that enters body and is converted into an active form by biologic process is | Prodrug |
| Branch of pharmacology that deals with undesirable effects of chemicals on living system | Toxicology |
| Study of substances that interact with living system through chemical processes | Pharmacology |
| Ability to predict appropriate molecular structure of a drug on the basis of information about its biologic receptor | Rational drug design |
| Principal organ of biotransformation of drug | liver |
| Time required to change amount of drug in the body by one-half during elimination | half-life |
| If two preparations of a drug are the same in all intent and purposes, they are | bioequivalence |
| Characteristic of a drug that permits binding to its receptor sites via complementary bond | Drug shape |
| Fraction of unchanged drug reaching the systemic circulation is | Bioavailability |
| Intrathecal route of administration means the drug is through | Spinal cavity |
| Oral Route | Most convenient |
| Intravenous | Most rapid onset |
| Rectal route | Less 1st pass effect |
| Subcutaneous | Smaller volume and painful |
| Transdermal | Slow absorption, prolonged duration of action |
| Administration | Appropriate route |
| Distribution | Site of action |
| Absorption | To the blood stream |
| Biotransformation | Liver |
| Elimination | Thru feces and urine |
| Slow absorption | Transdermal |
| After rapid onset | inhalation |
| Intramuscular | may be painful |
| Inalation | 5 - less than 100% |
| Intramuscular | 75 - less than 100% |
| Rectal | 30 - less than 100% |
| Oral | 5 - less than 100% |
| Transdermal | 80 - less than 100% |
| Intravenous | 100% |
| Subcutaneous | 75 - less than 100% |
Created by:
happymatcha
Popular Pharmacology sets